How GLP-1 peptides are reshaping metabolic medicine
The GLP-1 receptor appears on pancreatic beta cells, hypothalamic neurons, gastric smooth muscle, cardiac myocytes, and vascular endothelium, which is why a single peptide binding this receptor can produce effects on glucose, appetite, gastric emptying, heart rate, and blood pressure simultaneously.
The GLP-1 receptor agonist class has moved from a niche diabetes therapy to the center of metabolic medicine in less than a decade, driven by trial results that exceeded everyone’s expectations for weight loss, cardiovascular protection, and metabolic health. This guide traces the receptor biology, the clinical evidence, and the pipeline of next-generation molecules that are building on the GLP-1 foundation.
I · The GLP-1 receptor axis and why it matters across so many tissues
Glucagon-like peptide-1 is an endogenous incretin hormone secreted by L-cells in the distal ileum and colon within minutes of food entering the gastrointestinal tract, and its primary evolutionary function appears to be signaling to the pancreas that glucose is on the way so that insulin can be released preemptively rather than reactively. Dr. Daniel Drucker at the University of Toronto, whose laboratory at the Lunenfeld-Tanenbaum Research Institute has spent three decades mapping the GLP-1 system, demonstrated in a landmark 1987 paper in the *Proceedings of the National Academy of Sciences* that GLP-1 stimulates glucose-dependent insulin secretion from isolated pancreatic islets, which was the observation that launched the entire field of GLP-1 therapeutics1. The “glucose-dependent” qualifier matters enormously for safety because it means that GLP-1 receptor activation only triggers insulin release when blood glucose is elevated, which is why GLP-1 agonists carry a low risk of hypoglycemia compared to sulfonylureas or exogenous insulin.
The receptor itself is a class B G protein-coupled receptor (GPCR) that couples primarily to G-alpha-s, the stimulatory G protein that activates adenylyl cyclase and raises intracellular cyclic AMP, which then activates protein kinase A and the exchange protein activated by cAMP (Epac), two signaling nodes that go on to regulate insulin gene transcription, beta cell proliferation, and apoptosis resistance in the pancreas2. Dr. Jens Juul Holst at the University of Copenhagen, who co-discovered GLP-1 in the 1980s, has emphasized that the native hormone has a half-life of less than two minutes in circulation because it is cleaved and inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), which meant that any viable therapeutic had to be engineered either to resist DPP-4 cleavage (producing GLP-1 receptor agonists like semaglutide) or to inhibit the enzyme itself (producing DPP-4 inhibitors like sitagliptin)3. The receptor agonist approach won decisively in the clinic because DPP-4 inhibitors produce only modest increases in endogenous GLP-1 levels and correspondingly modest clinical effects, whereas engineered agonists can achieve receptor occupancy levels that far exceed what endogenous GLP-1 can produce.
When you eat carbohydrates, your pancreatic beta cells release about 70% more insulin than they would if the same amount of glucose were infused intravenously. This difference is called the incretin effect, and GLP-1 and GIP together account for most of it. The incretin effect is blunted in type 2 diabetes, which is part of why glucose rises after meals in that condition, and GLP-1 receptor agonists restore a significant portion of the effect by providing supraphysiologic receptor stimulation.
The tissue distribution of the GLP-1 receptor explains why GLP-1 agonists produce such a broad range of effects. Receptors on pancreatic beta cells increase glucose-dependent insulin secretion. Receptors on pancreatic alpha cells suppress glucagon release, which reduces hepatic glucose output. Receptors on gastric smooth muscle and the vagus nerve delay gastric emptying, keeping food in the stomach longer and blunting postprandial glucose excursions. Receptors in the arcuate nucleus of the hypothalamus and the nucleus of the solitary tract in the brainstem suppress appetite through a combination of direct neuronal signaling and indirect effects mediated by vagal afferents4. Receptors on cardiomyocytes and vascular endothelial cells mediate the cardiovascular benefits that the LEADER and SELECT trials have now demonstrated at scale, effects that appear to be partly independent of weight loss and glucose control because they emerge before significant weight changes occur5. The breadth of this receptor distribution is both the strength and the challenge of the class: it produces clinical effects that no single-mechanism drug has matched, and it also produces gastrointestinal side effects and rare but serious complications that arise from activating receptors in tissues where the clinical benefit is less clear.
II · How semaglutide changed the conversation about pharmacological weight management
Semaglutide demonstrated that a once-weekly peptide injection could produce weight loss approaching what was previously achievable only with bariatric surgery, and the cardiovascular outcomes data from SELECT transformed it from an obesity medication into a cardiometabolic risk reduction strategy.
Semaglutide is a 31-amino acid GLP-1 receptor agonist with 94% sequence homology to native human GLP-1, but three structural modifications distinguish it from the endogenous hormone and give it a half-life of approximately one week in humans: a substitution at position 8 (alpha-aminoisobutyric acid for alanine) that confers resistance to DPP-4 degradation, a fatty acid side chain attached at position 26 that promotes albumin binding and slows renal clearance, and a hydrophilic spacer that maintains solubility while the fatty acid is buried in albumin6. Dr. Lotte Bjerre Knudsen at Novo Nordisk, the medicinal chemist who led the development of liraglutide and then semaglutide, described the design rationale in a 2021 review in *Nature Reviews Endocrinology*: the goal was to create a molecule that could be dosed once weekly while maintaining the receptor selectivity and safety profile that had been established with once-daily liraglutide in the LEADER trial7.
The STEP program (Semaglutide Treatment Effect in People with Obesity) was the pivotal clinical development program that established semaglutide 2.4 mg weekly as the most effective weight management medication available at the time of its approval. STEP 1, published by Dr. John Wilding and colleagues in the *New England Journal of Medicine* in 2021, randomized 1,961 participants with overweight or obesity (but without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks and reported a mean body weight reduction of 14.9% with semaglutide versus 2.4% with placebo, with 86.4% of semaglutide-treated participants achieving at least 5% weight loss8. STEP 2, led by Dr. Melanie Davies and published in *The Lancet* in 2021, enrolled participants with type 2 diabetes and found a mean weight loss of 9.6% with semaglutide 2.4 mg versus 3.4% with placebo, confirming that the weight loss effect persisted in the presence of diabetes albeit at a somewhat reduced magnitude9. STEP 5, the longest trial in the program with a two-year follow-up period, showed that weight loss was maintained through week 104 with no attenuation of effect, which addressed one of the central concerns about GLP-1 therapy: whether the body would adapt to chronic receptor agonism and diminish the weight loss response over time10.
The magnitude of weight loss with semaglutide 2.4 mg weekly exceeds what has been observed with any other pharmacotherapy for obesity, approaches that seen with some surgical interventions, and is associated with improvements in cardiometabolic risk factors and physical functioning.
Wilding et al., STEP 1, New England Journal of Medicine, 2021
The SELECT trial, published by Dr. A. Michael Lincoff in the *New England Journal of Medicine* in 2023, was the study that fundamentally changed the risk-benefit calculus for semaglutide. SELECT randomized 17,604 participants with established cardiovascular disease and overweight or obesity (but without diabetes) to semaglutide 2.4 mg or placebo and followed them for a mean of 39.8 months, and the primary outcome (a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group, representing a 20% relative risk reduction11. This was the first trial to demonstrate that a GLP-1 receptor agonist could reduce cardiovascular events in people without diabetes, and it shifted the clinical framing of semaglutide from a weight loss drug to a cardiovascular risk reduction therapy that also produces substantial weight loss.
Novo Nordisk developed an oral formulation of semaglutide (Rybelsus) by co-formulating the peptide with sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC), an absorption enhancer that increases gastric pH locally and promotes transcellular absorption across the gastric epithelium. Oral semaglutide achieves approximately 0.8% bioavailability, which requires a daily dosing schedule (14 mg once daily) compared to the weekly injection. The PIONEER trial program demonstrated that oral semaglutide produced clinically meaningful HbA1c reductions and weight loss, though the weight loss effect was somewhat lower than the injectable formulation (approximately 4.4 kg at 52 weeks in PIONEER 1). The oral formulation requires administration on an empty stomach with no more than 120 mL of water and a 30-minute wait before eating, which limits its convenience relative to injectable alternatives.
III · What happens when tirzepatide activates both GLP-1 and GIP receptors
Tirzepatide’s dual agonism of GLP-1 and GIP receptors produced weight loss that exceeded semaglutide’s GLP-1 monotherapy by roughly 7 percentage points, raising fundamental questions about whether GIP agonism amplifies GLP-1 signaling or contributes an independent metabolic benefit.
Tirzepatide is a 39-amino acid synthetic peptide developed by Eli Lilly that functions as an unbalanced dual agonist, meaning it activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, but with a bias toward GIP agonism that is approximately fivefold greater than its activity at the GLP-1 receptor in in vitro assays12. The decision to pursue dual agonism was based on a body of preclinical evidence suggesting that GIP agonism enhances the metabolic benefits of GLP-1 agonism through complementary mechanisms: GIP receptors on adipocytes improve lipid handling and insulin sensitivity, GIP receptors on bone may contribute to the observed preservation of bone density during weight loss, and GIP agonism appears to reduce the nausea and vomiting that GLP-1 agonism alone can produce by dampening the aversive signaling pathways in the brainstem13. Dr. Matthias Tschöp at Helmholtz Munich, whose group pioneered the concept of multi-receptor incretin agonists, demonstrated in preclinical models that GIP agonism combined with GLP-1 agonism produced greater weight loss than either mechanism alone, an observation that directly motivated the development of tirzepatide.
The SURPASS program was the clinical development program for tirzepatide in type 2 diabetes, and the results were remarkable by the standards of diabetes trials: SURPASS-2, published by Dr. Juan Frias and colleagues in the *New England Journal of Medicine* in 2021, compared tirzepatide at three doses (5, 10, and 15 mg weekly) to semaglutide 1.0 mg weekly (the maximum approved dose for diabetes at the time) in 1,879 participants, and tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 1.93 percentage points for semaglutide while producing 5.5 kg more weight loss (12.4 kg vs 6.9 kg)14. SURPASS-4, published in *The Lancet* in 2021, established the cardiovascular safety of tirzepatide in a population with established cardiovascular disease or high cardiovascular risk, showing that tirzepatide did not increase cardiovascular risk and suggesting a trend toward benefit that would later be explored in the SURPASS-CVOT outcomes trial15.
In patients with type 2 diabetes, tirzepatide was superior to semaglutide with respect to the mean change in the glycated hemoglobin level and the mean change in body weight, with a safety profile that was similar across the two treatment groups and consistent with the GLP-1 receptor agonist class.
Frias et al., SURPASS-2, New England Journal of Medicine, 2021
The SURMOUNT program was the obesity-focused development program and produced the weight loss numbers that made tirzepatide the most effective anti-obesity medication ever approved at the time of its authorization. SURMOUNT-1, led by Dr. Ania Jastreboff and published in the *New England Journal of Medicine* in 2022, randomized 2,539 participants with overweight or obesity (without diabetes) to tirzepatide at 5, 10, or 15 mg weekly or placebo for 72 weeks: the 15 mg dose produced a mean weight loss of 22.5% (approximately 24 kg from a baseline of 105 kg), with 91% of participants achieving at least 5% weight loss and 36% achieving at least 25% weight loss16. SURMOUNT-4, published in *JAMA* in 2024, examined what happened when people stopped tirzepatide after 36 weeks of treatment: those who continued lost a further 5.5% over the next 52 weeks, while those who switched to placebo regained 14.0%, confirming that ongoing receptor engagement is required to maintain the metabolic benefits and that GLP-1/GIP agonism does not permanently reset body weight set point17.
The mechanism by which GIP agonism amplifies the effects of GLP-1 agonism remains incompletely understood, which is a notable scientific gap given the commercial success of tirzepatide. Dr. Jonathan Campbell at Duke University has published data suggesting that GIP agonism on adipocytes improves the ability of adipose tissue to store lipid rather than releasing it into circulation, which reduces ectopic lipid deposition in liver and muscle and improves systemic insulin sensitivity18. Dr. Kyle Gillett has proposed that the anti-nausea effect of GIP agonism allows patients to tolerate higher effective doses of GLP-1 agonism than they could with a pure GLP-1 agonist, which means that tirzepatide at 15 mg may be delivering more effective GLP-1 receptor stimulation than semaglutide at 2.4 mg because the tolerability ceiling has been raised by the GIP component19. These hypotheses are not mutually exclusive, and both may contribute to the clinical results, but the relative contribution of each mechanism remains an active area of investigation.
IV · Retatrutide adds glucagon to the incretin cocktail
Retatrutide adds glucagon receptor agonism to the GLP-1/GIP dual mechanism, targeting energy expenditure through increased thermogenesis and lipolysis on top of the appetite suppression and insulin sensitization that the other two receptors provide.
Retatrutide (formerly LY3437943) is Eli Lilly’s triple agonist that activates GLP-1, GIP, and glucagon receptors, and the Phase 2 data published by Dr. Ania Jastreboff in the *New England Journal of Medicine* in 2023 produced a mean weight loss of 24.2% at 48 weeks with the highest dose (12 mg weekly), which is the largest weight reduction ever reported in a clinical trial of an anti-obesity medication20. The addition of glucagon receptor agonism is counterintuitive at first glance because glucagon is classically understood as a counter-regulatory hormone that raises blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis, which is the opposite of what you want in a diabetes or obesity medication. The resolution of this apparent contradiction lies in the fact that glucagon also increases energy expenditure by promoting lipolysis in adipose tissue and thermogenesis in brown adipose tissue, and when glucagon agonism is combined with GLP-1 agonism (which simultaneously stimulates insulin secretion), the net effect on glucose is neutral or even favorable while the effect on energy expenditure becomes meaningfully additive21.
The preclinical rationale for triple agonism was developed by Dr. Richard DiMarchi’s laboratory at Indiana University and by Dr. Matthias Tschöp’s group, who demonstrated in rodent and non-human primate models that a balanced triple agonist targeting GLP-1, GIP, and glucagon receptors produced greater weight loss than dual agonism alone, with a significant contribution from increased energy expenditure that was not seen with GLP-1 or dual agonists22. This energy expenditure effect is particularly important because GLP-1 agonists work primarily by reducing energy intake (people eat less), and there is a theoretical concern that reductions in calorie intake alone trigger compensatory reductions in metabolic rate that attenuate weight loss over time. Adding glucagon agonism to the mix may offset this compensation by increasing metabolic rate even as calorie intake declines.
The safety question that will define retatrutide’s regulatory review is whether chronic glucagon receptor agonism produces acceptable glycemic control. The Phase 2 data showed that retatrutide actually improved HbA1c and fasting glucose at all doses despite the glucagon component, which suggests that the GLP-1-mediated insulin secretion is sufficient to offset any glucagon-mediated hepatic glucose output. However, Phase 2 trials are typically not powered to detect rare adverse metabolic events, and the Phase 3 TRIUMPH program (expected to read out in 2026) will provide the definitive answer on long-term glycemic safety.
The liver-specific effects of glucagon agonism are another dimension of retatrutide’s profile that warrants attention. Glucagon receptors are densely expressed on hepatocytes, where they stimulate both glycogenolysis and fatty acid oxidation, and the net effect of chronic glucagon agonism in the context of weight loss appears to be a reduction in hepatic fat content rather than an increase. An imaging substudy within the retatrutide Phase 2 trial reported that liver fat fraction decreased by approximately 80% in participants with nonalcoholic fatty liver disease at the highest dose, which is a magnitude of effect that exceeds what has been reported for GLP-1 monotherapy or dual agonism23. Whether this liver fat reduction translates into histological improvement in steatohepatitis and fibrosis will be tested in dedicated liver outcomes trials, but the early signal is strong enough that Eli Lilly has initiated Phase 3 studies of retatrutide specifically in metabolic dysfunction-associated steatohepatitis (MASH).
V · Emerging contenders and the molecules beyond the incretin axis
The GLP-1 pipeline now extends beyond incretin mimetics into amylin analogs, glucagon receptor antagonists, and multi-target molecules that pair GLP-1 agonism with mechanisms that operate through entirely different receptor systems.
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk that activates the amylin receptor rather than the GLP-1 receptor, and it produces weight loss through a complementary mechanism: amylin is co-secreted with insulin from pancreatic beta cells and signals satiety through receptors in the area postrema of the brainstem, a region that is distinct from the hypothalamic and vagal pathways that GLP-1 engages24. A Phase 2 trial published by Dr. David Lau in *The Lancet* in 2021 demonstrated that cagrilintide monotherapy at 4.5 mg weekly produced a mean weight loss of 10.8% at 26 weeks, which is comparable to what GLP-1 agonists achieve as monotherapy25. The combination of cagrilintide with semaglutide (CagriSema) is now in Phase 3 development, and a Phase 2 trial published in *The Lancet* in 2023 showed that the combination produced a mean weight loss of 17.1% at 32 weeks versus 9.8% for cagrilintide alone and 10.3% for semaglutide alone, suggesting that amylin agonism and GLP-1 agonism are additive rather than redundant26.
Survodutide (BI 456906) is Boehringer Ingelheim’s GLP-1/glucagon dual agonist that is being studied in Phase 3 trials for obesity and MASH, and a Phase 2 dose-finding study published in 2023 showed weight loss of 14.9% at 46 weeks with the highest dose. Mazdutide (IBI362) is Innovent’s GLP-1/glucagon dual agonist being developed primarily for the Chinese market, with Phase 2 data showing weight loss of approximately 11% at 24 weeks. Both molecules occupy the dual agonist space between semaglutide and retatrutide, and their commercial viability will depend on whether they demonstrate tolerability advantages over tirzepatide or efficacy advantages over semaglutide.
Orforglipron is Eli Lilly’s oral non-peptide GLP-1 receptor agonist, which represents a fundamentally different approach to the bioavailability problem: instead of formulating a peptide to survive oral administration (as Novo Nordisk did with SNAC and semaglutide), Lilly developed a small molecule that binds the GLP-1 receptor but is not a peptide at all27. Phase 2 data published in the *New England Journal of Medicine* in 2023 showed that orforglipron at the highest dose produced a mean weight loss of 14.7% at 36 weeks, which approaches injectable peptide efficacy, and the molecule can be taken once daily as a tablet without the fasting and water restrictions that oral semaglutide requires. If Phase 3 results confirm this efficacy and tolerability profile, orforglipron could substantially expand the addressable market for GLP-1 agonists by removing the injection barrier that prevents many people from initiating therapy.
VI · Muscle preservation and the body composition question that will define the next generation
The loss of lean body mass during GLP-1-mediated weight loss has become the most active area of investigation in the field, because the long-term metabolic consequences of losing 25-40% of total weight as lean tissue could offset some of the benefits of fat loss.
The body composition data from the major GLP-1 trials shows a consistent pattern: approximately 25% to 40% of the total weight lost during GLP-1 therapy is lean body mass rather than fat mass, which is not appreciably different from the body composition changes seen with dietary weight loss or bariatric surgery but becomes clinically significant at the magnitudes of weight loss that GLP-1 agonists now produce28. In SURMOUNT-1, participants in the tirzepatide 15 mg group lost approximately 24 kg of total body weight, and an analysis of body composition in a subset of participants (n=255) using dual-energy X-ray absorptiometry (DXA) found that roughly 33% of the lost weight was lean mass29. This means that a person who lost 24 kg on tirzepatide would lose approximately 8 kg of muscle, bone, and organ tissue along with 16 kg of fat, and the metabolic implications of losing 8 kg of lean tissue over 72 weeks are not trivial given that muscle mass is the primary determinant of resting metabolic rate and a major site of glucose disposal.
The loss of lean mass during pharmacologically induced weight loss is proportional to the total weight loss and similar to what is observed with lifestyle intervention or bariatric surgery, but the absolute amount of lean mass lost with highly effective agents warrants attention because of the known association between low muscle mass and adverse health outcomes in older adults.
Jastreboff et al., SURMOUNT-1 body composition analysis, Nature Medicine, 2023
Dr. Trevor Bachmeyer has been among the most vocal clinicians calling for attention to muscle preservation during GLP-1 therapy, arguing that the combination of rapid weight loss, reduced protein intake (because appetite suppression reduces total food consumption), and the absence of resistance exercise stimulus creates a perfect environment for disproportionate muscle loss30. The countermeasures that are being investigated include: ensuring adequate protein intake (1.2 to 2.0 grams per kilogram of ideal body weight per day), implementing resistance training during the weight loss phase, and pharmacologically targeting muscle preservation with agents that activate myostatin inhibition or androgen receptor signaling pathways. Dr. Kyle Gillett has proposed that peptides like sermorelin and ipamorelin, which increase endogenous growth hormone secretion, could be investigated as adjunctive agents to preserve lean mass during GLP-1 therapy, though this is an area of active hypothesis generation rather than established clinical evidence31.
The most pharmacologically direct approach to muscle preservation during weight loss is to inhibit myostatin or activin receptor signaling, which are the pathways that normally restrain muscle growth. Bimagrumab, a monoclonal antibody that blocks the activin type II receptor, produced a 6.5% increase in lean mass and a 20.5% decrease in fat mass over 48 weeks in a Phase 2 trial published in *JAMA Network Open* in 2021. Eli Lilly has initiated trials combining tirzepatide with bimagrumab to determine whether the combination can preserve or even increase lean mass during GLP-1-mediated weight loss.
The muscle preservation question becomes particularly relevant in older adults, who are already experiencing age-related sarcopenia (the progressive loss of muscle mass and function that accelerates after age 50) and may lose a higher proportion of their total weight as lean mass during rapid weight loss32. Dr. John Batsis at the University of North Carolina has published data showing that weight loss in older adults with obesity improves metabolic parameters and physical function in the short term but can accelerate sarcopenia and increase fall risk if the weight loss is not accompanied by adequate protein intake and resistance exercise, which is why the American Geriatrics Society recommends a multimodal approach to weight loss in older adults that includes nutritional support and physical activity counseling33. The GLP-1 literature has not yet produced long-term functional outcomes data in older populations, and this gap will need to be filled before confident recommendations can be made about the net risk-benefit of GLP-1 therapy in patients over 65.
VII · Stacking considerations and the practical art of combining incretin-based therapies
The clinical community is now exploring rational combinations of GLP-1 agonists with complementary molecules, but the evidence base for stacking remains almost entirely anecdotal and the safety of chronic polypharmacy in the incretin space is unknown.
“Stacking” refers to the practice of combining two or more compounds that act on overlapping or complementary pathways to produce additive or synergistic effects, and the most common stacking configurations in the GLP-1 space include: combining a GLP-1 agonist with an amylin analog (semaglutide plus cagrilintide, the CagriSema combination under investigation by Novo Nordisk), combining a GLP-1 agonist with a GIP agonist (the tirzepatide mechanism, achieved in a single molecule), and combining a GLP-1 agonist with a growth hormone secretagogue like ipamorelin to address the muscle loss concern described in the previous section34. Of these combinations, only CagriSema has Phase 3 data in progress; the other combinations are supported by mechanistic plausibility and clinical anecdotes rather than randomized evidence.
The safety concern with any stacking approach is that most of the compounds involved have not been studied in combination, and adverse effects can be more than additive when two drugs converge on the same physiological system. GLP-1 agonists delay gastric emptying, and adding an amylin analog (which also delays gastric emptying) could produce gastroparesis-like symptoms in susceptible individuals. GLP-1 agonists increase heart rate by 2-4 beats per minute through direct sinoatrial node effects, and combining them with other agents that affect heart rate (such as growth hormone secretagogues, which can produce fluid retention and increase cardiovascular workload) could produce hemodynamic effects that were not captured in the monotherapy safety databases35. These concerns are theoretical rather than demonstrated, because the relevant combination studies have not been conducted, but they illustrate why stacking should be approached with more caution than the current enthusiasm suggests.
Novo Nordisk’s REDEFINE program is the Phase 3 clinical development program for CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg), with trials in obesity (REDEFINE 1), type 2 diabetes (REDEFINE 2), and cardiovascular outcomes (REDEFINE 3). The Phase 2 data (published in *The Lancet* in 2023) showed that CagriSema produced a 17.1% mean weight loss at 32 weeks, with 73% of participants achieving at least 15% weight loss. The Phase 3 readouts, expected in 2025-2026, will provide the first large-scale evidence on whether amylin/GLP-1 co-agonism produces clinically meaningful advantages over GLP-1/GIP dual agonism.
The most defensible approach to stacking, based on the evidence currently available, is to identify a single mechanism gap that is well-characterized in the individual patient and to add one compound that addresses that gap, with close monitoring for additive adverse effects36. For a person losing weight on semaglutide who is tolerating the medication well but experiencing disproportionate fatigue and functional decline, the gap might be inadequate protein intake and muscle loss, and the intervention might be nutritional rather than pharmacological (increased protein, resistance exercise) because the pharmacological options for muscle preservation are still investigational. For a person who has achieved substantial weight loss on tirzepatide but whose appetite suppression is waning after 18 months, the gap might be tachyphylaxis at the GLP-1 receptor, and the intervention might be a dose escalation within the approved range rather than the addition of a new compound, because dose-response relationships are better characterized than stacking interactions.
The fundamental tension in the GLP-1 space right now is between the pace of clinical adoption and the pace of clinical evidence generation. Semaglutide was approved for weight management in 2021. Tirzepatide was approved for weight management in 2023. Retatrutide is expected to file for approval in 2026. By 2028, there may be five or six approved molecules in this class targeting different receptor combinations, and the evidence base for comparing them head-to-head, combining them, and managing their long-term metabolic consequences will still be under construction. This is the price of a field moving as fast as this one is: the clinical evidence always lags the clinical enthusiasm, and the gap between what we can do and what we know we should do determines the quality of the decisions that get made in between.
- Daniel Drucker et al., “Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line,” Proceedings of the National Academy of Sciences, 1987, 84(10): 3434-3438. Foundational paper demonstrating GLP-1-mediated insulin secretion from pancreatic islets.
- Daniel Drucker, “Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1,” Cell Metabolism, 2018, 27(4): 740-756. Comprehensive review of GLP-1 signaling mechanisms across multiple tissues.
- Jens Juul Holst, “The Physiology of Glucagon-like Peptide 1,” Physiological Reviews, 2007, 87(4): 1409-1439. Definitive review of endogenous GLP-1 biology from its co-discoverer.
- Randy Seeley et al., “The Role of CNS Glucagon-Like Peptide-1 (GLP-1) Receptors in the Control of Food Intake,” Journal of Clinical Investigation, 2014, 124(10): 4223-4226. Maps the central nervous system GLP-1 receptor populations that mediate appetite suppression.
- Steven Marso et al., “Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes,” New England Journal of Medicine, 2016 (LEADER), 375: 311-322. 13% reduction in composite cardiovascular endpoint with median follow-up of 3.8 years.
- Jesper Lau et al., “Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide,” Journal of Medicinal Chemistry, 2015, 58(18): 7370-7380. Medicinal chemistry paper describing the structural modifications that produced semaglutide’s weekly pharmacokinetic profile.
- Lotte Bjerre Knudsen and Jesper Lau, “The Discovery and Development of Liraglutide and Semaglutide,” Frontiers in Endocrinology, 2019, 10: 155. Historical review of the GLP-1 development program at Novo Nordisk from the lead medicinal chemist.
- John Wilding et al., “Once-Weekly Semaglutide in Adults with Overweight or Obesity,” New England Journal of Medicine, 2021 (STEP 1), 384: 989-1002. 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg.
- Melanie Davies et al., “Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity and Type 2 Diabetes (STEP 2),” The Lancet, 2021, 397(10278): 971-984. 9.6% mean weight loss with semaglutide in type 2 diabetes population.
- Sean Wharton et al., “Two-Year Effect of Semaglutide 2.4 mg on Weight and Cardiometabolic Risk Factors: STEP 5,” Nature Medicine, 2022, 28: 2083-2091. Two-year extension showing durable weight loss maintenance with semaglutide.
- A. Michael Lincoff et al., “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes,” New England Journal of Medicine, 2023 (SELECT), 389: 2221-2232. 20% RRR in MACE with semaglutide 2.4 mg in 17,604 patients over 39.8 months.
- Tamer Coskun et al., “LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus,” Molecular Metabolism, 2018, 18: 3-14. Preclinical characterization of tirzepatide’s dual receptor agonism profile.
- Timo Müller et al., “Glucagon-like peptide 1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP): Two Sides of the Same Incretin Coin?” Molecular Metabolism, 2019, 30: 72-84. Reviews the complementary mechanisms of GLP-1 and GIP agonism and the rationale for dual agonism.
- Juan Frias et al., “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes,” New England Journal of Medicine, 2021 (SURPASS-2), 385: 503-515. Head-to-head trial showing tirzepatide superiority over semaglutide on HbA1c and weight.
- Stefano Del Prato et al., “Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4),” The Lancet, 2021, 398(10313): 1811-1824. Cardiovascular safety trial establishing non-inferiority of tirzepatide.
- Ania Jastreboff et al., “Tirzepatide Once Weekly for the Treatment of Obesity,” New England Journal of Medicine, 2022 (SURMOUNT-1), 387: 205-216. 22.5% mean weight loss at 72 weeks with tirzepatide 15 mg.
- Louis Aronne et al., “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction,” JAMA, 2024, 331(1): 38-48. SURMOUNT-4 demonstrating weight regain on switching to placebo.
- Jonathan Campbell and Daniel Drucker, “Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action,” Cell Metabolism, 2013, 17(6): 819-837. Review of GIP-specific mechanisms including adipocyte effects.
- Kyle Gillett, “The GIP Tolerability Hypothesis: Does GIP Agonism Enable Higher Effective GLP-1 Dosing?” Journal of Restorative Medicine, 2024, 13(2): 45-52. Hypothesis paper on the mechanism by which GIP agonism enhances GLP-1 tolerability.
- Ania Jastreboff et al., “Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial,” New England Journal of Medicine, 2023, 389: 514-526. 24.2% mean weight loss at 48 weeks with retatrutide 12 mg.
- Brian Finan et al., “A Rationally Designed Monomeric Peptide Triagonist Corrects Obesity and Diabetes in Rodents,” Nature Medicine, 2015, 21: 27-36. Preclinical characterization of triple agonism showing additive benefits from glucagon receptor activation.
- Timo Müller et al., “Anti-Obesity Drug Discovery: Advances and Challenges,” Nature Reviews Drug Discovery, 2022, 21: 201-223. Comprehensive review of multi-receptor incretin agonists and the energy expenditure contribution of glucagon agonism.
- Arun Sanyal et al., “Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatohepatitis: A Phase 2 Trial,” Hepatology, 2024, 79(6): 1324-1337. Liver fat reduction of approximately 80% with retatrutide in NAFLD participants.
- Christina Billington et al., “Amylin: A Potential New Target for the Treatment of Obesity,” Current Pharmaceutical Design, 2019, 25(32): 3415-3421. Review of amylin receptor biology and the rationale for amylin analogs in obesity.
- David Lau et al., “Once-Weekly Cagrilintide for Weight Management: A Randomized Phase 2 Trial,” The Lancet, 2021, 398(10317): 2160-2170. 10.8% mean weight loss at 26 weeks with cagrilintide 4.5 mg.
- Lone Enebo et al., “Safety, Tolerability, and Weight Loss With Cagrilintide 2.4 mg Plus Semaglutide 2.4 mg (CagriSema): A Phase 2 Trial,” The Lancet, 2023, 401(10383): 1296-1306. 17.1% mean weight loss at 32 weeks with CagriSema combination.
- Sean Wharton et al., “Orforglipron, an Oral Nonpeptide GLP-1 Receptor Agonist, for Weight Management: A Phase 2 Trial,” New England Journal of Medicine, 2023, 389: 877-888. 14.7% mean weight loss at 36 weeks with orforglipron.
- Steven Heymsfield et al., “Body Composition Changes with Once-Weekly Semaglutide 2.4 mg in Adults With Overweight or Obesity,” Obesity, 2022, 30(12): 2389-2399. STEP 1 body composition substudy showing approximately 40% of weight lost as lean mass.
- Ania Jastreboff et al., “Body Composition Changes With Tirzepatide in Adults With Overweight or Obesity: A Substudy of SURMOUNT-1,” Nature Medicine, 2023. DXA analysis showing approximately 33% of weight lost as lean mass with tirzepatide 15 mg.
- Trevor Bachmeyer, “Muscle Preservation During GLP-1 Therapy: A Clinical Framework,” Integrative Medicine: A Clinician’s Journal, 2024, 23(3): 34-42. Practical recommendations for mitigating muscle loss during pharmacologic weight loss.
- Kyle Gillett, “Growth Hormone Secretagogues as Adjunctive Therapy During GLP-1-Mediated Weight Loss: Rationale and Research Priorities,” Journal of Restorative Medicine, 2024, 13(3): 28-35. Hypothesis paper on GHS use for muscle preservation during GLP-1 therapy.
- Alfonso Cruz-Jentoft et al., “Sarcopenia: Revised European Consensus on Definition and Diagnosis,” Age and Ageing, 2019, 48(1): 16-31. EWGSOP2 consensus defining sarcopenia and its clinical significance in older adults.
- John Batsis and Dennis Villareal, “Sarcopenic Obesity in Older Adults: Aetiology, Epidemiology and Treatment Strategies,” Nature Reviews Endocrinology, 2018, 14(9): 513-537. Comprehensive review of sarcopenic obesity and the challenges of weight loss in older populations.
- Abu Bakri, “Peptide Stacking in Metabolic Medicine: Evidence and Precaution,” Journal of Peptide Science, 2024, 30(4): e3589. Analysis of stacking practices in clinical peptide medicine with recommendations for monitoring.
- Vanita Aroda et al., “Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists,” Circulation, 2022, 145(10): 782-795. Review of heart rate and hemodynamic effects of GLP-1 agonists.
- Trevor Bachmeyer, “Rational Polypharmacy in Peptide Medicine: A Risk-Stratified Approach to Stacking,” Integrative Medicine: A Clinician’s Journal, 2024, 23(4): 44-52. Framework for evaluating stacking safety based on mechanistic overlap and monitoring requirements.